WO2006095086A3 - Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence. - Google Patents

Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence. Download PDF

Info

Publication number
WO2006095086A3
WO2006095086A3 PCT/FR2006/000510 FR2006000510W WO2006095086A3 WO 2006095086 A3 WO2006095086 A3 WO 2006095086A3 FR 2006000510 W FR2006000510 W FR 2006000510W WO 2006095086 A3 WO2006095086 A3 WO 2006095086A3
Authority
WO
WIPO (PCT)
Prior art keywords
traceability
neurodegeneration
anomalies
cellular cycle
oncology
Prior art date
Application number
PCT/FR2006/000510
Other languages
English (en)
Other versions
WO2006095086A8 (fr
WO2006095086A2 (fr
Inventor
Laurence Faure
Original Assignee
Laurence Faure
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR0502257A external-priority patent/FR2882753A1/fr
Priority claimed from FR0502258A external-priority patent/FR2882754A1/fr
Priority to EP06726042A priority Critical patent/EP1869209A2/fr
Priority to US11/908,103 priority patent/US9523688B2/en
Application filed by Laurence Faure filed Critical Laurence Faure
Publication of WO2006095086A2 publication Critical patent/WO2006095086A2/fr
Publication of WO2006095086A3 publication Critical patent/WO2006095086A3/fr
Publication of WO2006095086A8 publication Critical patent/WO2006095086A8/fr
Priority to US12/047,173 priority patent/US8039439B2/en
Priority to US13/226,024 priority patent/US9193774B2/en
Priority to US14/486,852 priority patent/US20160108477A1/en
Priority to US15/383,251 priority patent/US10983129B2/en
Priority to US17/232,413 priority patent/US20220283168A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un nouveau test diagnostic et/ou pronostic pour le cancer. Plus particulièrement, l'invention concerne la protéine humaine LIV21, son utilisation comme marqueurs diagnostics et pronostic du cancer. L'invention concerne également des méthodes de traitement du cancer et des maladies neurodégénératives ainsi que des compositions destinées à cet effet.
PCT/FR2006/000510 2005-03-07 2006-03-07 Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence. WO2006095086A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP06726042A EP1869209A2 (fr) 2005-03-07 2006-03-07 Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
US11/908,103 US9523688B2 (en) 2005-03-07 2006-03-07 Diagnosis method and treatment for cancer using liv21 proteins and E2F1/E2F4 biomarkers
US12/047,173 US8039439B2 (en) 2005-03-07 2008-03-12 Cellular cycle anomalies for targeting oncology and neurodegeneration
US13/226,024 US9193774B2 (en) 2005-03-07 2011-09-06 Traceability of cellular cycle anomalies targeting oncology and neurodegeneration
US14/486,852 US20160108477A1 (en) 2005-03-07 2014-09-15 Traceability of Cellular Cycle Anomalies Targeting Oncology and Neurodegeneration
US15/383,251 US10983129B2 (en) 2005-03-07 2016-12-19 Method for the detection of cancer cells by localization of peptides in nucleus as compared to cytoplasm
US17/232,413 US20220283168A1 (en) 2005-03-07 2021-04-16 Method for the detection of cancer cells by localization of peptides in nucleus as compared to cytoplasm

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
FR0502258 2005-03-07
FR0502258A FR2882754A1 (fr) 2005-03-07 2005-03-07 Methodes diagnostics et pronostics du cancer du sein utilisant liv21
FR0502257A FR2882753A1 (fr) 2005-03-07 2005-03-07 Tracabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence
FR0502257 2005-03-07

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US11/908,103 A-371-Of-International US9523688B2 (en) 2005-03-07 2006-03-07 Diagnosis method and treatment for cancer using liv21 proteins and E2F1/E2F4 biomarkers
US90810307A A-371-Of-International 2005-03-07 2007-09-07
US12/047,173 Continuation-In-Part US8039439B2 (en) 2005-03-07 2008-03-12 Cellular cycle anomalies for targeting oncology and neurodegeneration
US15/383,251 Division US10983129B2 (en) 2005-03-07 2016-12-19 Method for the detection of cancer cells by localization of peptides in nucleus as compared to cytoplasm

Publications (3)

Publication Number Publication Date
WO2006095086A2 WO2006095086A2 (fr) 2006-09-14
WO2006095086A3 true WO2006095086A3 (fr) 2007-06-07
WO2006095086A8 WO2006095086A8 (fr) 2007-08-16

Family

ID=36938994

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/000510 WO2006095086A2 (fr) 2005-03-07 2006-03-07 Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.

Country Status (3)

Country Link
US (3) US9523688B2 (fr)
EP (1) EP1869209A2 (fr)
WO (1) WO2006095086A2 (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1869209A2 (fr) * 2005-03-07 2007-12-26 Laurence Faure Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
KR101297917B1 (ko) 2005-08-30 2013-08-27 어드밴스드 테크놀러지 머티리얼즈, 인코포레이티드 대안적인 불화 붕소 전구체를 이용한 붕소 이온 주입 방법,및 주입을 위한 대형 수소화붕소의 형성 방법
US8314221B2 (en) * 2006-09-07 2012-11-20 Laurence Claude Faure Pharmacodiagnostic test targeting oncology and neurodegeneration
US20130324478A1 (en) 2008-09-08 2013-12-05 Laurence Faure Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration
US20110021011A1 (en) 2009-07-23 2011-01-27 Advanced Technology Materials, Inc. Carbon materials for carbon implantation
US8062965B2 (en) 2009-10-27 2011-11-22 Advanced Technology Materials, Inc. Isotopically-enriched boron-containing compounds, and methods of making and using same
US8598022B2 (en) 2009-10-27 2013-12-03 Advanced Technology Materials, Inc. Isotopically-enriched boron-containing compounds, and methods of making and using same
US8138071B2 (en) 2009-10-27 2012-03-20 Advanced Technology Materials, Inc. Isotopically-enriched boron-containing compounds, and methods of making and using same
TWI386983B (zh) 2010-02-26 2013-02-21 Advanced Tech Materials 用以增進離子植入系統中之離子源的壽命及性能之方法與設備
US8779383B2 (en) 2010-02-26 2014-07-15 Advanced Technology Materials, Inc. Enriched silicon precursor compositions and apparatus and processes for utilizing same
WO2012030679A2 (fr) 2010-08-30 2012-03-08 Advanced Technology Materials, Inc. Appareil et procédé pour préparer des composés ou leurs intermédiaires à partir d'un matériau solide, et utilisation desdits composés et intermédiaires
TWI583442B (zh) 2011-10-10 2017-05-21 恩特葛瑞斯股份有限公司 Ｂ２ｆ４之製造程序
CN108565198A (zh) 2012-02-14 2018-09-21 恩特格里斯公司 用于改善注入束和源寿命性能的碳掺杂剂气体和协流
EP2971280B1 (fr) * 2013-03-15 2018-08-29 Arizona Board of Regents on behalf of Arizona State University Compositions et procédés de microréseaux de biocapteurs
US11062906B2 (en) 2013-08-16 2021-07-13 Entegris, Inc. Silicon implantation in substrates and provision of silicon precursor compositions therefor

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064736A2 (fr) * 2000-03-03 2001-09-07 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Nouveaux composes servant a reguler la proliferation et/ou la differenciation de cellules, et applications biologiques associees

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6339066B1 (en) * 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
IL140716A0 (en) * 1998-07-06 2002-02-10 Use of inhibitors of protein kinase c epsilon to treat pain
EP2338899A1 (fr) * 2001-01-18 2011-06-29 The Board Of Trustees Of The Leland Stanford Junior University Peptides destinés à l'activation et à l'inhibition de delta PKC
WO2003080640A1 (fr) * 2002-03-07 2003-10-02 Ludwig Institute For Cancer Research Genes de cellules endotheliales sanguines et lymphatiques
US20040259816A1 (en) * 2002-10-01 2004-12-23 Pandol Stephen J. Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
EP1869209A2 (fr) * 2005-03-07 2007-12-26 Laurence Faure Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
US20130324478A1 (en) * 2008-09-08 2013-12-05 Laurence Faure Pharmacodiagnosis Test Targeting Oncology and Neurodegeneration

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001064736A2 (fr) * 2000-03-03 2001-09-07 Institut National De La Sante Et De La Recherche Medicale (I.N.S.E.R.M.) Nouveaux composes servant a reguler la proliferation et/ou la differenciation de cellules, et applications biologiques associees

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"AFFYMETRIX CATALOG", AFFYMETRIX PRODUCT CATALOG, July 2002 (2002-07-01), pages 1, XP002267612 *
"Human Genome U95 Set", ANNOUNCEMENT AFFYMETRIX, April 2000 (2000-04-01), pages 1 - 2, XP002284454 *
BARNES D M ET AL: "P53, APOPTOSIS, AND BREAST CANCER", JOURNAL OF MAMMARY GLAND BIOLOGY AND NEOPLASIA, PLENUM PRESS, NEW YORK, NY,, US, vol. 1, no. 2, April 1996 (1996-04-01), pages 163 - 175, XP009002087, ISSN: 1083-3021 *
CRISANTI PATRICIA ET AL: "Cloning and characterization of a novel transcription factor involved in cellular proliferation arrest: PATF", ONCOGENE, BASINGSTOKE, HANTS, GB, vol. 20, no. 39, 6 September 2001 (2001-09-06), pages 5475 - 5483, XP000926674, ISSN: 0950-9232 *
DATABASE Geneseq [online] 1 July 2004 (2004-07-01), "Human BEC/LEC-related protein sequence SeqID129.", XP002402779, retrieved from EBI accession no. GSP:ADN95207 Database accession no. ADN95207 *
KNAUF J A ET AL: "Involvement of protein kinase Cepsilon (PKCepsilon) in thyroid cell death. A truncated chimeric PKCepsilon cloned from a thyroid cancer cell line protects thyroid cells from apoptosis.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. 13 AUG 1999, vol. 274, no. 33, 13 August 1999 (1999-08-13), pages 23414 - 23425, XP002402849, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
EP1869209A2 (fr) 2007-12-26
US20170115296A1 (en) 2017-04-27
US10983129B2 (en) 2021-04-20
WO2006095086A8 (fr) 2007-08-16
US20100285971A1 (en) 2010-11-11
WO2006095086A2 (fr) 2006-09-14
US9523688B2 (en) 2016-12-20
US20220283168A1 (en) 2022-09-08

Similar Documents

Publication Publication Date Title
WO2006095086A3 (fr) Traçabilite des anomalies du cycle cellulaire ciblant l'oncologie et la neurodegenerescence.
WO2007016548A3 (fr) Procedes et compositions a base de micro-arn pour le diagnostic, le pronostic et le traitement du cancer du sein
WO2007081720A3 (fr) Procédés et compositions basés sur des micro-arn et s'appliquant au diagnostic, au pronostic et au traitement du cancer du poumon
IL182423A0 (en) Disubstituted pyrazolobenzodiazepines useful as inhibitors for cdk2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer
WO2006015079A3 (fr) Agents de liaison de la famille erm et leur utilisation dans le diagnostic et le traitement d'etats proliferatifs
WO2008100805A3 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
MX2009012625A (es) Metodos para el tratamiento, diagnostico y deteccion de trastornos asociados con el fgf21.
DK1893196T3 (da) Diarylhydantoin-forbindelse
WO2006105486A3 (fr) Nouveau gene suppresseur de tumeur, et compositions et procedes de fabrication et d'utilisation de ce gene
WO2007056049A3 (fr) Profilage moleculaire de cancer
WO2007053648A3 (fr) Compositions et méthodes pour traiter et diagnostiquer un cancer
WO2008121767A3 (fr) Polypeptides cousus
WO2007053573A3 (fr) Traitement du cancer au moyen de sorafenib
WO2006089087A9 (fr) Compositions, trousses et methodes servant a effectuer l'identification, l'evaluation, la prophylaxie et la therapie du cancer
WO2007025303A3 (fr) Antiandrogenes non steroidiens
WO2009092108A3 (fr) Biomarqueurs pour le diagnostic et le traitement du cancer du pancréas
WO2007141280A3 (fr) protéines
SI1858929T1 (sl) Diagnoza raka prostate
WO2009113814A3 (fr) Marqueur protéique utilisé pour le diagnostic précoce du cancer du foie
EP1862804A4 (fr) Méthode pour diagnostiquer le cancer de la prostate
WO2007033167A3 (fr) Compositions et methodes de detection et de traitement du cancer
WO2008112290A3 (fr) Utilisation du récepteur ephb4 comme marqueur diagnostique et cible thérapeutique dans le cancer de l'ovaire
EP1870711A4 (fr) Protéine marqueur utilisée lors du diagnostic du cancer du pancréas
WO2008092002A3 (fr) Compositions et procédés pour le traitement et le diagnostic du cancer du pancréas
IL189377A0 (en) Combinations comprising dmxaa for the treatment of cancer

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 11908103

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006726042

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWW Wipo information: withdrawn in national office

Country of ref document: RU

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06726042

Country of ref document: EP

Kind code of ref document: A2

WWP Wipo information: published in national office

Ref document number: 2006726042

Country of ref document: EP